Gadolinium-DTPA-dextran: A macromolecular MR blood pool contrast agent
Gadolinium-DTPA-dextran: A macromolecular MR blood pool contrast agent
复制标题
DOI：
10.1016/j.acra.2004.11.016
复制
发表时间：
2004-12-01
影响因子：
4.8
通讯作者：
Mattrey, RF
中科院分区：
文献类型：
--
作者：
Sirlin, CB;Vera, DR;Mattrey, RF
理由和目标。磁共振（MR）成像血池剂为血管和肿瘤成像提供了许多优势。本研究的目的是测试钆-二乙烯三胺五乙酸-葡聚糖（[Gd] DTPA-葡聚糖）作为一种新的水溶性大分子血池剂的MR成像。合成了[Gd] DTPA-右旋糖酐（每个右旋糖酐187个钆原子，分子量165 kD，直径17.6 rim）。在1.5 T膝关节线圈中扫描15只患有大腿VX 2肿瘤的麻醉新西兰白色家兔。冠状位3D MR血管造影序列在静脉推注[Gd] DTPA-葡聚糖（提供0.05（n = 4）或0.1 mmol/kg（n = 8）的钆）或[Gd] DTPA-二甲酰胺（BMA）（提供0.1 mmol/kg（n = 3）的钆）之前和之后的几个时间点获得，直至72小时。主动脉、腔静脉和肿瘤边缘的时间增强曲线采用单变量一般线性模型进行比较。在所有时间点，[Gd]DTPA-dextran组与[Gd]DTPA-BMA组相比，腔静脉和主动脉相对于水模的对比增强明显更大（P < 0.01）。两种剂量的[Gd]DTPA-dextran在峰值时肿瘤边缘增强强度均低于[Gd]DTPA-BMA（P < 0.05）。两种剂量的[Gd]DTPA-dextran在1h时肿瘤边缘增强与[Gd]DTPA-BMA相当，24 h时增强更明显（P < 0.05）。[Gd] DTPA-葡聚糖是一种新型的大分子MR造影剂，其可以被合成为携带高密度的钆原子而没有分子内交联。它提供了显着更长的血管停留时间比传统的钆螯合物，并显示了磁共振血池成像的承诺。
Rationale and Objectives. Magnetic resonance (MR) imaging blood pool agents offer numerous advantages for vascular and tumor imaging. The purpose of this study was to test gadolinium-diethylenetriaminepentaacetate-dextran ([Gd]DTPA-dextran) as a new water soluble macromolecular blood pool agent for MR imaging.Materials and Methods. [Gd]DTPA-dextran (187 gadolinium atoms per dextran, molecular weight 165 kD, diameter 17.6 rim) was synthesized. Fifteen anesthetized New Zealand White rabbits with thigh VX2 tumors were scanned in a knee coil at 1.5T. Coronal 3D MR angiographic sequences were obtained before and at several time points up to 72 hours after the intravenous bolus injection of [Gd]DTPA-dextran providing gadolinium at either 0.05 (n = 4) or 0.1 mmol/kg (n = 8) or [Gd]DTPA-bismethylamide (BMA) providing gadolinium at 0.1 mmol/kg (n = 3). Time enhancement curves for aorta, cava, and tumor rim were compared by univariate General Linear Model.Results. Contrast enhancement of cava and aorta relative to a water phantom were significantly greater at all time points after either dose of [Gd]DTPA-dextran than after [Gd]DTPA-BMA (P < 0.01). Tumor rim enhancement was less intense for either dose of [Gd]DTPA-dextran at peak than for [Gd]DTPA-BMA (P < 0.05). Tumor rim enhancement with both doses of [Gd]DTPA-dextran became equivalent to that of [Gd]DTPA-BMA at one hour and was greater at 24 hours (P < 0.05).Conclusion. [Gd]DTPA-dextran is a new macromolecular MR contrast agent that can be synthesized to carry a high density of gadolinium atoms without intra-molecular cross-linking. It provides significantly greater vascular residence time than a conventional gadolinium chelate and shows promise for MR blood pool imaging.